Trial · NCT00736996
Pioglitazone Or Exercise to Treat Mild Cognitive Impairment (MCI)
NCT00736996, Phase 2, Completed, University of Colorado, Denver; results first posted 2016-01-15
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Pioglitazone Or Exercise to Treat Mild Cognitive Impairment (MCI). Trials, record NCT00736996. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00736996
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Pioglitazone Or Exercise to Treat Mild Cognitive Impairment (MCI)
- NCT number
- NCT00736996
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 78 participants, actual
- Lead sponsor
- University of Colorado, Denver
- Conditions
- Mild Cognitive Impairment
- Interventions
- Pioglitazone, Placebo, Endurance Exercise Training
- First posted
- 2008-08-18
- Last updated
- 2016-01-15
- Results first posted
- 2016-01-15
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Cognitive Performance | Baseline to 6 months | Participants were administered a neuropsychological testing battery consisting of assessments in four cognitive domains: memory (Visual Reproduction II, Logical Memory II, Rey Auditory Verbal Learning Test), language (Boston Naming Test , Category Fluency), visuospatial (Block Design, Picture Completion), and executive function (Trail Making Test B, Digit Symbol Test). Raw test scores for these primary cognitive domain measures were transformed into age-adjusted scaled scores with a mean of 10 and a standard deviation (SD) of 3, with higher numbers indicating better cognitive performance, using the Mayo's Older American Normative Studies data. Cognitive domain scores were calculated as the arithmetic mean of the normatively derived scaled scores for all of the tests in that domain. |
| Secondary | Change in Insulin Resistance | Baseline to 6 months | Change in whole body glucose disposal rate (mg/kg/min) calculated during a single-stage (40 mU/m2/min), 3-hour hyperinsulinemic, euglycemic clamp |
| Secondary | Change in Peak Oxygen Uptake (VO2 Peak) | Baseline to 6 months | Peak oxygen consumption (VO2 peak, ml/kg/min) was determined by open circuit spirometry during a standard treadmill stress test (modified Balke protocol). |
Source ClinicalTrials.gov
Outcomes3
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change in Cognitive Performance | Baseline to 6 months | units on a scale | NUMBER | |
| SECONDARY | Change in Insulin Resistance | Baseline to 6 months | mg/kg/min | NUMBER | |
| SECONDARY | Change in Peak Oxygen Uptake (VO2 Peak) | Baseline to 6 months | ml/kg/min | NUMBER |
Source ClinicalTrials.gov
Results by group18
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change in Cognitive Performance | Pioglitazone | Memory domain | 0.8 | 95% Confidence Interval -1.4 to 2.9 | units on a scale |
| Change in Cognitive Performance | Endurance Exercise Training | Memory domain | 0.7 | 95% Confidence Interval -1.5 to 2.8 | units on a scale |
| Change in Cognitive Performance | Placebo | Memory domain | 1.2 | 95% Confidence Interval -1.0 to 3.4 | units on a scale |
| Change in Cognitive Performance | Pioglitazone | Language domain | 0.4 | 95% Confidence Interval -1.8 to 2.6 | units on a scale |
| Change in Cognitive Performance | Endurance Exercise Training | Language domain | 0.6 | 95% Confidence Interval -1.6 to 2.8 | units on a scale |
| Change in Cognitive Performance | Placebo | Language domain | 0.4 | 95% Confidence Interval -1.9 to 2.6 | units on a scale |
| Change in Cognitive Performance | Pioglitazone | Visuospatial domain | 0.3 | 95% Confidence Interval -1.7 to 2.3 | units on a scale |
| Change in Cognitive Performance | Endurance Exercise Training | Visuospatial domain | 1.1 | 95% Confidence Interval -0.9 to 3.1 | units on a scale |
| Change in Cognitive Performance | Placebo | Visuospatial domain | 0.8 | 95% Confidence Interval -1.2 to 2.8 | units on a scale |
| Change in Cognitive Performance | Pioglitazone | Executive function domain | 1.0 | 95% Confidence Interval -0.9 to 3.0 | units on a scale |
1 to 10 of 18Source ClinicalTrials.gov
See all 18 results by groupParticipant flow9
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Pioglitazone | 25 | |
| Overall Study | STARTED | Endurance Exercise Training | 26 | |
| Overall Study | STARTED | Placebo | 27 | |
| Overall Study | COMPLETED | Pioglitazone | 24 | |
| Overall Study | COMPLETED | Endurance Exercise Training | 17 | |
| Overall Study | COMPLETED | Placebo | 25 | |
| Overall Study | NOT COMPLETED | Pioglitazone | 1 | |
| Overall Study | NOT COMPLETED | Endurance Exercise Training | 9 | |
| Overall Study | NOT COMPLETED | Placebo | 2 |
Source ClinicalTrials.gov
Adverse events63
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Musculoskeletal | Musculoskeletal and connective tissue disorders | Pioglitazone | 3 | 25 | 4 |
| other | Musculoskeletal | Musculoskeletal and connective tissue disorders | Endurance Exercise Training | 11 | 26 | 11 |
| other | Musculoskeletal | Musculoskeletal and connective tissue disorders | Placebo | 6 | 27 | 6 |
| other | Cardiovascular | Cardiac disorders | Pioglitazone | 4 | 25 | 5 |
| other | Cardiovascular | Cardiac disorders | Endurance Exercise Training | 2 | 26 | 2 |
| other | Cardiovascular | Cardiac disorders | Placebo | 4 | 27 | 5 |
| other | Dermatologic | Skin and subcutaneous tissue disorders | Pioglitazone | 3 | 25 | 4 |
| other | Dermatologic | Skin and subcutaneous tissue disorders | Endurance Exercise Training | 1 | 26 | 1 |
| other | Dermatologic | Skin and subcutaneous tissue disorders | Placebo | 5 | 27 | 5 |
| other | Gastrointestinal | Gastrointestinal disorders | Pioglitazone | 5 | 25 | 6 |
1 to 10 of 63Source ClinicalTrials.gov
See all 63 adverse eventsAdverse event totals9
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Pioglitazone | ||
| Total, all-cause mortality | Endurance Exercise Training | ||
| Total, all-cause mortality | Placebo | ||
| Total, other adverse events | Pioglitazone | 18 | 25 |
| Total, other adverse events | Endurance Exercise Training | 19 | 26 |
| Total, other adverse events | Placebo | 23 | 27 |
| Total, serious adverse events | Pioglitazone | 3 | 25 |
| Total, serious adverse events | Endurance Exercise Training | 1 | 26 |
| Total, serious adverse events | Placebo | 3 | 27 |
Source ClinicalTrials.gov
Papers5
The papers the trial lists on ClinicalTrials.gov.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| R01AG028746 | Pioglitazone & Exercise Effects on Older Aldults with MCI and Metabolic Syndrome | SCHWARTZ, ROBERT S | UNIVERSITY OF COLORADO DENVER | NATIONAL INSTITUTE ON AGING | 2008 to 2010 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests7
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Category Fluency | Primary outcome | ConductCognition |
| Picture Naming Test | Primary outcome | ConductCognition |
| Short Story Recall | Primary outcome | ConductCognition |
| Symbol Coding | Primary outcome | ConductCognition |
| Trail Making Test A | Primary outcome | ConductCognition |
| Trail Making Test B | Primary outcome | ConductCognition |
| Verbal Learning | Primary outcome | ConductCognition |
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00736996
GET https://conductscience.org/api/trials/v1/NCT00736996/events?page=2